Oaktree Acquisition Corp. III Life Sciences Unit
OACCU
NASDAQ Global Select10.73
USD
- -
- -
Oaktree Acquisition Corp. III Life Sciences Unit
OACCU
(NASDAQ Global Select)
Recent
price
10.73
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Oaktree Acquisition Corp. III (OACCU), a blank check company sponsored by affiliates of Oaktree Capital Management, L.P., focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses, with a particular emphasis on the life sciences sector. The company offers redeemable units comprising Class A ordinary shares and public warrants, enabling investors to participate in its pursuit of acquisition targets; it does not have significant operations other than these activities. Headquartered in Los Angeles, California, Oaktree Acquisition Corp. III was formed in 2023 and operates principally in the United States, targeting life sciences companies including those in biotechnology, pharmaceuticals, diagnostics, and medical devices. The company's core offerings center on its sponsor-supported structure, backed by Oaktree Capital Management's expertise in specialty investing and its track record in life sciences transactions; it seeks targets with strong growth potential in innovative therapies, drug development, and health technology. Geographically, it primarily evaluates opportunities in North America but considers global life sciences firms with U.S.-centric operations. Oaktree Acquisition Corp. III maintains no subsidiaries at present and operates as a standalone special purpose acquisition company (SPAC) without a parent entity beyond its sponsor relationships. In recent developments, Oaktree Acquisition Corp. III has not announced any mergers, acquisitions, or business combinations as of late 2025, remaining in the pre-transaction phase typical for SPACs. No major funding rounds, partnerships, product launches, or strategic shifts have been publicly disclosed in the last 1-2 years, reflecting its ongoing search for a suitable life sciences target. The company continues to hold investor capital in trust, with units traded on Nasdaq under OACCU, positioning it for potential de-SPAC activity amid a recovering SPAC market.